Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - simvastatin - tablett, filmdrasjert - 20 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - simvastatin - tablett, filmdrasjert - 40 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - simvastatin - tablett, filmdrasjert - 80 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibrose - andre åndedrettsprodukter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Den europeiske union - norsk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - gefitinib mylan er indisert som monoterapi for behandling av voksne pasienter med lokalt avansert eller metastatisk ikke‑liten celle lunge kreft (nsclc) med aktiverende mutasjoner i egfr‑tk.

Norge - norsk - Statens legemiddelverk

aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 40 mg

Norge - norsk - Statens legemiddelverk

aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 10 mg

Norge - norsk - Statens legemiddelverk

aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 20 mg

Norge - norsk - Statens legemiddelverk

aristo pharma gmbh - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 80 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.